Healthcare / Medical DevicesTokyo
$1091.00
+8.00 (+0.74%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 25% · confianza 25%
FCF escenarios
weak_data · normalized FCF $26.7B · quality 46.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
39/100
D
Piotroski
8/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$138.0B
P/E
23.9x
↑EV/EBITDA
6.8x
↓ROE
7.4%
↑Gross Margin
46.0%
↓Debt/Equity
1.80
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+2.0%
FCF CAGR
-8.3%
FCF margin
8.4%
FCF / Net income
2.89x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $361.59B · net income $10.48B · FCF $30.33B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $361.59B | $361.59B | $353.90B | $356.43B | $340.45B |
| Net Income | $10.48B | $10.48B | $-12.89B | $-3.22B | $-8.46B |
| EBITDA | $51.96B | $51.96B | $30.15B | $49.42B | $41.60B |
| EPS | 82.58 | 82.58 | -102.48 | -25.84 | -70.78 |
| Gross Margin | 46.0% | 46.0% | 44.6% | 47.5% | 48.5% |
| Operating Margin | 6.3% | 6.3% | 0.5% | 5.8% | 2.5% |
| Net Margin | 2.9% | 2.9% | -3.6% | -0.9% | -2.5% |
| Balance Sheet | |||||
| Debt/Equity | 1.80 | 1.80 | 2.04 | 2.12 | 2.27 |
| Current Ratio | 0.93 | 0.93 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $30.33B | $30.33B | $26.67B | $9.86B | $39.32B |
| Returns | |||||
| ROE | 7.4% | 7.4% | -9.2% | -2.3% | -6.2% |
| Valuation | |||||
| P/E | 23.87 | 23.87 | — | — | — |
| EV/EBITDA | 6.82 | 6.82 | 12.55 | 8.32 | 10.54 |
| P/B | 0.98 | 0.98 | 1.01 | 1.30 | 1.67 |
| Growth & Yield | |||||
| Revenue Growth | 2.2% | 2.2% | -0.7% | 4.7% | — |
| EPS Growth | 180.6% | 180.6% | -296.6% | 63.5% | — |
| Dividend Yield | 3.9% | 3.9% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
5.4%
EPS terminal req.
$96.81
Spread vs growth
175.1%
5Y implied EPS CAGR
7.2%
EPS terminal req.
$117.14
Spread vs growth
173.3%
10Y implied EPS CAGR
8.6%
EPS terminal req.
$188.65
Spread vs growth
172.0%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+18.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-102.48 → 82.58
Residual
+14.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.